Duloxetine HCL DR Capsules
SAM.GOV Due: September 5, 2025 at 07:00 PM UTC
In-Active Combined Synopsis/Solicitation Source Url

Summary

The opportunity for Duloxetine HCL DR Capsules involves the procurement of this pharmaceutical product by the Defense Logistics Agency (DLA) under solicitation number SPE2D2-25-R-0010. Contractors with expertise in pharmaceutical manufacturing and distribution are encouraged to bid on this opportunity, as it requires compliance with specific regulations and standards for drug production and delivery. The contract will likely involve the supply of Duloxetine HCL DR Capsules to meet the needs of military and government healthcare facilities, emphasizing the importance of quality assurance and timely delivery. Interested bidders should be prepared to demonstrate their capability to meet the stringent requirements outlined in the solicitation documents.
Description

SPE2D2-25-R-0010 Duloxetine HCL DR Solicitation

Entities
DOD
Department of Defense
DLA
Defense Logistics Agency
NAICS
325412
Set Aside
None
Place of Performance
Point of Contact
Full Name Email Phone Type
Christopher Newman [email protected] 4457377371 primary
Jason Wray [email protected] 4457376304 secondary
Attachments
  • Duloxetine+HCL+DR+SPE2D225R0010+Solicitation+release.pdf
  • SPE2D225R0010+0001+released.pdf
  • SPE2D225R0010+0002+released.pdf
  • SPE2D225R0010+0003+released.pdf
  • SPE2D225R0010+0004+released.pdf
  • SPE2D225R0010+0005+released.PDF
  • SPE2D225R0010+0006+released.pdf
  • SPE2D225R0010+0006+updates.pdf